TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2595-2600

  Lu, Hou Gen ^a   Zhan, Wang ^b   Yan, Lin ^a   Qin, Rui Ying ^c   Yan, Yi Peng ^c   Yang, Zhen Jiang ^c   Liu, Gui Chao ^d   Li, Gui Qin ^c   Wang, Hai Feng ^e   Li, Xing Liang ^f   Li, Zhi ^f   Gao, Lu ^g   Chen, Guo Qing ^h  

^a Jingzhou Central Hospital   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Xin Xiang Medical University   (China)

^d Nanyang City Center Hospital   (China)

^e DeepBlue Technology   (China)

^f Shanghai Research Institute of Building Science Co   (China)

^g NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^h Shanghai Jiao Tong University School of Medicine   (China)

Author keywords

Breast cancer; HDAC inhibitor; TET1; TSA

Indexed keywords

GELATINASE A; GELATINASE B; PROTEIN; STROMELYSIN; TET1 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRICHOSTATIN A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; ONCOPROTEIN; TET1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; WOUND CLOSURE; WOUND HEALING; ADULT; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84907186669     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2517     Document Type: Article

References (43)

1. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55-63, 2003.
2. Mohanam S, Sawaya R, McCutcheon I, Ali Osman F, Boyd D and Rao JS: Modulation of in vitro invasion of human glioblastoma cells by urokinase type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147, 1993.
3. Rao JS: Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 3: 489-501, 2003.
4. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993.
5. Horikoshi M: Histone acetylation: from code to web and router via intrinsically disordered regions. Curr Pharm Des 19: 5019-5042, 2013.
6. Gräff J and Tsai LH: Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 14: 97-111, 2013.
7. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y and Jones DR: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF kappa B through the Akt pathway. J Biol Chem 278: 18980-18989, 2003.
8. Brochier C, Dennis G, Rivieccio MA, McLaughlin K, Coppola G, Ratan RR and Langley B: Specific acetylation of p53 by HDAC inhibition prevents DNA damage induced apoptosis in neurons. J Neurosci 33: 8621-8632, 2013.
9. Sachweh MC, Drummond CJ, Higgins M, Campbell J and Laín S: Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis 4: e533, 2013.
10. Cheung WL, Briggs SD and Allis CD: Acetylation and chromosomal functions. Curr Opin Cell Biol 12: 326-333, 2000.
11. Van Lint C, Emiliani S and Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253, 1996.
12. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545, 2004.
13. Song J, Noh JH, Lee JH, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268, 2005.
14. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004.
15. Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168, 2004.
16. McGarry LC, Winnie JN and Ozanne BW: Invasion of v Fos(FBR) transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23: 5284-5292, 2004.
17. Marks PA, Richon VM, Kelly WK, Chiao JH and Miller T: Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 259: 269-281, 2004.
18. Vigushin DM, Ali S, Pace PE, et al: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
19. Tarasenko N, Nudelman A, Tarasenko I, et al: Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN 7 are superior to those of the clinically tested AN 9 (Pivanex). Clin Exp Metastasis 25: 703-716, 2008.
20. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
21. Liu LT, Chang HC, Chiang LC and Hung WC: Histone deacetylase inhibitor up regulates RECK to inhibit MMP 2 activation and cancer cell invasion. Cancer Res 63: 3069-3072, 2003.
22. Hsu CH, Peng KL, Kang ML, et al: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2: 568-579, 2012.
23. Yang H, Liu Y, Bai F, et al: Tumor development is associated with decrease of TET gene expression and 5 methylcytosine hydroxylation. Oncogene 32: 663-669, 2013.
24. Asrani K, Keri RA, Galisteo R, et al: The HER2 and heregulin beta1 (HRG) inducible TNFR superfamily member Fn14 promotes HRG driven breast cancer cell migration, invasion, and MMP9 expression. Mol Cancer Res 11: 393-404, 2013.
25. Brown SA, Ghosh A and Winkles JA: Full length, membrane anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF kappaB pathway. J Biol Chem 285: 17432-17441, 2010.
26. Grimaldi C, Pisanti S, Laezza C, et al: Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312: 363-373, 2006.
27. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler Stevenson WG: Tumor cell invasion inhibited by TIMP 2. J Natl Cancer Inst 83: 775-779, 1991.
28. Baker AH, George SJ, Zaltsman AB, Murphy G and Newby AC: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP 3. Br J Cancer 79: 1347-1355, 1999.
29. Jinga D, Stefanescu M, Blidaru A, Condrea I, Pistol G and Matache C: Serum levels of matrix metalloproteinases MMP 2 and MMP 9 and their tissue natural inhibitors in breast tumors. Roum Arch Microbiol Immunol 63: 141-158, 2004.
30. Sier CF, Kubben FJ, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP 2 and MMP 9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996.
31. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
32. Taby R and Issa JP: Cancer epigenetics. CA Cancer J Clin 60: 376-392, 2010.
33. Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol Sci 12: 4465-4487, 2011.
34. Namdar M, Perez G, Ngo L and Marks PA: Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 107: 20003-20008, 2010.
35. Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165, 2006.
36. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE: Synergistic activation of functional estrogen receptor (ER) alpha by DNA methyltransferase and histone deacetylase inhibition in human ER alpha negative breast cancer cells. Cancer Res 61: 7025-7029, 2001.
37. Travaglini L, Vian L, Billi M, Grignani F and Nervi C: Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41: 225-234, 2009.
38. Kim SH, Kang HJ, Na H and Lee MO: Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein. Breast Cancer Res 12: R22, 2010.
39. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589, 2003.
40. Williams K, Christensen J, Pedersen MT, et al: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473: 343-348, 2011.
41. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
42. Hatziapostolou M and Iliopoulos D: Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68: 1681-1702, 2011.
43. Chik F and Szyf M: Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32: 224-232, 2011.